Brief: Solid Biosciences Outlines Strategy For Leadership In Precision Genetic Medicines With Focus On Neuromuscular And Cardiac Diseases

Solid Biosciences

10/01/2023 13:07

Jan 10 (Reuters) - Solid Biosciences Inc  SLDB.O :
    * SOLID BIOSCIENCES OUTLINES STRATEGY FOR LEADERSHIP IN
PRECISION
GENETIC MEDICINES WITH FOCUS ON NEUROMUSCULAR AND CARDIAC
DISEASES
    * SOLID BIOSCIENCES INC - KEVIN TAN NAMED CHIEF FINANCIAL
OFFICER,
EXPERIENCE TO SUPPORT EXECUTION OF CORPORATE STRATEGY
    * SOLID BIOSCIENCES INC - ENTERS 2023 WITH APPROXIMATELY
$214
MILLION IN CASH AND INVESTMENTS; EXPECTED TO FUND KEY STRATEGIC
PRIORITIES INTO 2025
    * SOLID BIOSCIENCES INC - IND APPLICATION FOR SGT-003,
EXPECTED IN
2H-2023

Source text for Eikon:  ID:nGNX81ltNQ 
Further company coverage:  SLDB.O 
 ((reuters.briefs@thomsonreuters.com;))